Literature DB >> 26629254

Non-secreting multiple myeloma switches to IgD of lamda type: a case report and review of literature.

Lili Gao1, Qinlu Li1, Jinsong Kang2, Chunrui Li1, Jianfeng Zhou1.   

Abstract

We report a case of a woman, who initially presented with an non-secreting multiple myeloma, 11 months later, she was diagnosed as an IgD-secreting myeloma. In December, 2010, the patient's serum protein quantification and immunofixation electrophoresis (IFE) revealed polyclonal immunoglobulin with no evidence of monoclonal immunoglobulin. However, her bone marrow smears revealed an abnormal proliferation of atypical plasma cells (46.5%), so she was diagnosed as non-secreting multiple myeloma. After three cycles of administration of Velcade plus Dexamethasone (VD), she achieved a complete remission (CR). Unfortunately, on October 31, 2011, our patient was found to have a separate peak of monoclonal component on the γ-region of cellulose-acetate electrophoresis, and the serum immunofixation electrophoresis revealed the monoclonal component was IgD. Several months later, she presented with a large swelling of the left side of her neck. Microscopic examination of a biopsy specimen from the cervical mass showed a neoplastic plasma cell tumor and she died on January 28, 2013 from acute respiratory failure resulting from neoplastic plasma cells infiltration and infection. Here we report this rare case and review the literature for similar cases.

Entities:  

Keywords:  IgD-λ; Non-secreting multiple myeloma; immunofixation electrophoresis; relapse; serum free light chain

Year:  2015        PMID: 26629254      PMCID: PMC4659142     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  25 in total

1.  Extramedullary relapse of multiple myeloma associated with a shift in secretion from intact immunoglobulin to light chains.

Authors:  Mark A Dawson; Sushrut Patil; Andrew Spencer
Journal:  Haematologica       Date:  2007-01       Impact factor: 9.941

2.  Non-secretory myeloma: clinical and biologic implications.

Authors:  Rafael Fonseca
Journal:  Oncology (Williston Park)       Date:  2013-09       Impact factor: 2.990

3.  Immunoglobulin D myeloma--problems with diagnosing and staging (own experience and literature review).

Authors:  Małgorzata Kuliszkiewicz-Janus; Anna Zimny; Violetta Sokolska; Marek Saşiadek; Kazimierz Kuliczkowski
Journal:  Leuk Lymphoma       Date:  2005-07

4.  A two-stage model for development of antibody-producing cells.

Authors:  M D Cooper; A R Lawton; P W Kincade
Journal:  Clin Exp Immunol       Date:  1972-05       Impact factor: 4.330

5.  Immunofluorescent evidence for cellular control of synthesis of variable regions of light and heavy chains of immunoglobulins G and M by the same gene.

Authors:  A S Levin; H H Fudenberg; J E Hopper; S K Wilson; A Nisonoff
Journal:  Proc Natl Acad Sci U S A       Date:  1971-01       Impact factor: 11.205

6.  Nonsecretory multiple myeloma with amyloidosis. A case report and review of the literature.

Authors:  Evariste Gafumbegete; Susann Richter; Ludwig Jonas; Horst Nizze; Josef Makovitzky
Journal:  Virchows Arch       Date:  2004-07-29       Impact factor: 4.064

Review 7.  International Myeloma Working Group molecular classification of multiple myeloma: spotlight review.

Authors:  R Fonseca; P L Bergsagel; J Drach; J Shaughnessy; N Gutierrez; A K Stewart; G Morgan; B Van Ness; M Chesi; S Minvielle; A Neri; B Barlogie; W M Kuehl; P Liebisch; F Davies; S Chen-Kiang; B G M Durie; R Carrasco; Orhan Sezer; Tony Reiman; Linda Pilarski; H Avet-Loiseau
Journal:  Leukemia       Date:  2009-10-01       Impact factor: 11.528

8.  Nonsecretory multiple myeloma.

Authors:  Seshikanth Middela; Prakash Kanse
Journal:  Indian J Orthop       Date:  2009-10       Impact factor: 1.251

9.  SINGLE CELL STUDIES ON 19S ANTIBODY PRODUCTION.

Authors:  G J NOSSAL; A SZENBERG; G L ADA; C M AUSTIN
Journal:  J Exp Med       Date:  1964-03-01       Impact factor: 14.307

10.  A NEW CLASS OF HUMAN IMMUNOGLOBULINS. II. NORMAL SERUM IGD.

Authors:  D S ROWE; J L FAHEY
Journal:  J Exp Med       Date:  1965-01-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.